Sensitization of tumor necrosis factor α-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte- activating polypeptide II using recombinant vaccinia virus

Michael F X Gnant, Adam C. Berger, James Huang, Markus Puhlmann, Peter C. Wu, Maria J. Merino, David L. Bartlett, H. Richard Alexander, Steven K. Libutti

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Tumor necrosis factor α (TNF-α) is a proinflammatory cytokine with potent experimental antitumor activity. Its clinical use in cancer treatment is severely limited by its considerable toxicity after systemic administration, and it is currently confined to isolated limb and organ perfusion settings. In this report, we introduce a novel concept of TNF-α- based gene therapy using the TNF-sensitizing properties of endothelial cell monocyte-activating polypeptide II (EMAP-II). We hypothesized that transfer of the EMAP-H gene into established TNF-resistant human melanomas would render these tumors sensitive to subsequent systemic TNF-α treatment. To achieve tumor selective gene delivery, we constructed a recombinant vaccinia virus encoding the human EMAP-II gene (vvEMAP). In vitro transfection of human melanoma cells led to the production of EMAP-II by these cells. Supernatants of vvEMAP-transfected tumor cells mediated the induction of tissue factor in endothelial cells. We characterized the pattern of gene expression after systemic administration of a recombinant vaccinia virus encoding a reporter gene in a murine in vivo model of s.c. human melanoma. Gene expression in tumor tissue was increased 100-fold as compared with normal tissue, providing evidence for tumor-selective gene delivery. Finally, human melanomas in nude mice were sensitized in vivo by transferring the EMAP-II gene using vvEMAP. Subsequent systemic administration of TNF-α led to tumor regression and growth inhibition of these previously TNF-resistant tumors (P < 0.05). This approach using gene therapy to sensitize primarily unresponsive tumors toward TNF-α may enhance the usefulness of TNF-α in clinical treatment strategies by increasing the window for the therapeutic application of the cytokine, thus reducing the dose necessary for antitumor responses and subsequently reduce toxicity.

Original languageEnglish (US)
Pages (from-to)4668-4674
Number of pages7
JournalCancer Research
Volume59
Issue number18
StatePublished - Sep 15 1999
Externally publishedYes

Fingerprint

Vaccinia virus
Melanoma
Tumor Necrosis Factor-alpha
Genes
Endothelial Cells
Neoplasms
Genetic Therapy
Cytokines
Gene Expression
human TNF protein
small inducible cytokine subfamily E, member 1
Thromboplastin
Therapeutics
Reporter Genes
Nude Mice
Transfection
Extremities
Perfusion

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sensitization of tumor necrosis factor α-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte- activating polypeptide II using recombinant vaccinia virus. / Gnant, Michael F X; Berger, Adam C.; Huang, James; Puhlmann, Markus; Wu, Peter C.; Merino, Maria J.; Bartlett, David L.; Alexander, H. Richard; Libutti, Steven K.

In: Cancer Research, Vol. 59, No. 18, 15.09.1999, p. 4668-4674.

Research output: Contribution to journalArticle

Gnant, MFX, Berger, AC, Huang, J, Puhlmann, M, Wu, PC, Merino, MJ, Bartlett, DL, Alexander, HR & Libutti, SK 1999, 'Sensitization of tumor necrosis factor α-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte- activating polypeptide II using recombinant vaccinia virus', Cancer Research, vol. 59, no. 18, pp. 4668-4674.
Gnant, Michael F X ; Berger, Adam C. ; Huang, James ; Puhlmann, Markus ; Wu, Peter C. ; Merino, Maria J. ; Bartlett, David L. ; Alexander, H. Richard ; Libutti, Steven K. / Sensitization of tumor necrosis factor α-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte- activating polypeptide II using recombinant vaccinia virus. In: Cancer Research. 1999 ; Vol. 59, No. 18. pp. 4668-4674.
@article{61605283949742beb092d82cf99d7f55,
title = "Sensitization of tumor necrosis factor α-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte- activating polypeptide II using recombinant vaccinia virus",
abstract = "Tumor necrosis factor α (TNF-α) is a proinflammatory cytokine with potent experimental antitumor activity. Its clinical use in cancer treatment is severely limited by its considerable toxicity after systemic administration, and it is currently confined to isolated limb and organ perfusion settings. In this report, we introduce a novel concept of TNF-α- based gene therapy using the TNF-sensitizing properties of endothelial cell monocyte-activating polypeptide II (EMAP-II). We hypothesized that transfer of the EMAP-H gene into established TNF-resistant human melanomas would render these tumors sensitive to subsequent systemic TNF-α treatment. To achieve tumor selective gene delivery, we constructed a recombinant vaccinia virus encoding the human EMAP-II gene (vvEMAP). In vitro transfection of human melanoma cells led to the production of EMAP-II by these cells. Supernatants of vvEMAP-transfected tumor cells mediated the induction of tissue factor in endothelial cells. We characterized the pattern of gene expression after systemic administration of a recombinant vaccinia virus encoding a reporter gene in a murine in vivo model of s.c. human melanoma. Gene expression in tumor tissue was increased 100-fold as compared with normal tissue, providing evidence for tumor-selective gene delivery. Finally, human melanomas in nude mice were sensitized in vivo by transferring the EMAP-II gene using vvEMAP. Subsequent systemic administration of TNF-α led to tumor regression and growth inhibition of these previously TNF-resistant tumors (P < 0.05). This approach using gene therapy to sensitize primarily unresponsive tumors toward TNF-α may enhance the usefulness of TNF-α in clinical treatment strategies by increasing the window for the therapeutic application of the cytokine, thus reducing the dose necessary for antitumor responses and subsequently reduce toxicity.",
author = "Gnant, {Michael F X} and Berger, {Adam C.} and James Huang and Markus Puhlmann and Wu, {Peter C.} and Merino, {Maria J.} and Bartlett, {David L.} and Alexander, {H. Richard} and Libutti, {Steven K.}",
year = "1999",
month = "9",
day = "15",
language = "English (US)",
volume = "59",
pages = "4668--4674",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Sensitization of tumor necrosis factor α-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte- activating polypeptide II using recombinant vaccinia virus

AU - Gnant, Michael F X

AU - Berger, Adam C.

AU - Huang, James

AU - Puhlmann, Markus

AU - Wu, Peter C.

AU - Merino, Maria J.

AU - Bartlett, David L.

AU - Alexander, H. Richard

AU - Libutti, Steven K.

PY - 1999/9/15

Y1 - 1999/9/15

N2 - Tumor necrosis factor α (TNF-α) is a proinflammatory cytokine with potent experimental antitumor activity. Its clinical use in cancer treatment is severely limited by its considerable toxicity after systemic administration, and it is currently confined to isolated limb and organ perfusion settings. In this report, we introduce a novel concept of TNF-α- based gene therapy using the TNF-sensitizing properties of endothelial cell monocyte-activating polypeptide II (EMAP-II). We hypothesized that transfer of the EMAP-H gene into established TNF-resistant human melanomas would render these tumors sensitive to subsequent systemic TNF-α treatment. To achieve tumor selective gene delivery, we constructed a recombinant vaccinia virus encoding the human EMAP-II gene (vvEMAP). In vitro transfection of human melanoma cells led to the production of EMAP-II by these cells. Supernatants of vvEMAP-transfected tumor cells mediated the induction of tissue factor in endothelial cells. We characterized the pattern of gene expression after systemic administration of a recombinant vaccinia virus encoding a reporter gene in a murine in vivo model of s.c. human melanoma. Gene expression in tumor tissue was increased 100-fold as compared with normal tissue, providing evidence for tumor-selective gene delivery. Finally, human melanomas in nude mice were sensitized in vivo by transferring the EMAP-II gene using vvEMAP. Subsequent systemic administration of TNF-α led to tumor regression and growth inhibition of these previously TNF-resistant tumors (P < 0.05). This approach using gene therapy to sensitize primarily unresponsive tumors toward TNF-α may enhance the usefulness of TNF-α in clinical treatment strategies by increasing the window for the therapeutic application of the cytokine, thus reducing the dose necessary for antitumor responses and subsequently reduce toxicity.

AB - Tumor necrosis factor α (TNF-α) is a proinflammatory cytokine with potent experimental antitumor activity. Its clinical use in cancer treatment is severely limited by its considerable toxicity after systemic administration, and it is currently confined to isolated limb and organ perfusion settings. In this report, we introduce a novel concept of TNF-α- based gene therapy using the TNF-sensitizing properties of endothelial cell monocyte-activating polypeptide II (EMAP-II). We hypothesized that transfer of the EMAP-H gene into established TNF-resistant human melanomas would render these tumors sensitive to subsequent systemic TNF-α treatment. To achieve tumor selective gene delivery, we constructed a recombinant vaccinia virus encoding the human EMAP-II gene (vvEMAP). In vitro transfection of human melanoma cells led to the production of EMAP-II by these cells. Supernatants of vvEMAP-transfected tumor cells mediated the induction of tissue factor in endothelial cells. We characterized the pattern of gene expression after systemic administration of a recombinant vaccinia virus encoding a reporter gene in a murine in vivo model of s.c. human melanoma. Gene expression in tumor tissue was increased 100-fold as compared with normal tissue, providing evidence for tumor-selective gene delivery. Finally, human melanomas in nude mice were sensitized in vivo by transferring the EMAP-II gene using vvEMAP. Subsequent systemic administration of TNF-α led to tumor regression and growth inhibition of these previously TNF-resistant tumors (P < 0.05). This approach using gene therapy to sensitize primarily unresponsive tumors toward TNF-α may enhance the usefulness of TNF-α in clinical treatment strategies by increasing the window for the therapeutic application of the cytokine, thus reducing the dose necessary for antitumor responses and subsequently reduce toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0033567895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033567895&partnerID=8YFLogxK

M3 - Article

C2 - 10493523

AN - SCOPUS:0033567895

VL - 59

SP - 4668

EP - 4674

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 18

ER -